As psilocybin and MDMA move deeper into psychiatric research and clinical practice, the conversation is shifting from therapeutic promise towards...

Australian psychedelic medicine company Emyria has brought former US Secretary of Veterans Affairs Dr David Shulkin into its strategy as...

For much of the past decade, the modern psychedelic renaissance has been accompanied by an unusually powerful media narrative. Drugs...

For much of the past decade, the psychedelic industry has revolved around companies developing the drugs themselves. Psilocybin, MDMA, LSD...

Definium Therapeutics has reported a second positive Phase 3 trial of its LSD-based treatment for generalized anxiety disorder, strengthening the...

A growing group of companies is developing pharmaceutical-grade psilocybin from mushrooms, creating the infrastructure needed to investigate whether the broader...

Entropy Neurodynamics has reported sustained improvements in treatment-resistant binge-eating disorder three months after patients received two infusions of its IV...

Long before psilocybin was being studied in hospitals and universities, and decades before psychedelic medicine became a commercial industry, an...

New research from The University of Texas MD Anderson Cancer Center suggests psilocybin may protect sensory nerves from damage caused...

Australian psychedelic medicine company Emyria Limited (ASX: EMD) has been selected by the US Food and Drug Administration (FDA) to...